{"id":48425,"date":"2024-01-25T11:25:58","date_gmt":"2024-01-25T03:25:58","guid":{"rendered":"https:\/\/biopioneer.com.tw\/?p=48425"},"modified":"2025-06-26T19:24:05","modified_gmt":"2025-06-26T11:24:05","slug":"sensistain-anti-claudin-18-2-antibody%e5%96%ae%e6%a0%aa%e6%8a%97%e9%ab%94-%e8%b2%a8%e8%99%9fhy500141","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=48425","title":{"rendered":"SensiStain\u2122 Anti-Claudin 18.2 Antibody\u55ae\u682a\u6297\u9ad4 \u00a0\u00a0| \u8ca8\u865fHY500141"},"content":{"rendered":"

SensiStain\u2122 Anti-Claudin 18.2 Antibody<\/a><\/strong>\u55ae\u682a\u6297\u9ad4<\/strong> \u00a0<\/strong>\u00a0<\/strong>| <\/strong>\u8ca8\u865fHY500141<\/strong><\/a><\/span><\/p>\n

SensiStain\u2122 Anti-Claudin 18.2 Antibody<\/p>\n

Claudin 18.2 \u53c3\u8207\u816b\u7624\u7684\u767c\u751f(tumor development)\u548c\u9032\u5c55\uff0c\u900f\u904e\u9223\u7368\u7acb\u7684\u7d30\u80de\u9ecf\u9644\u6d3b\u6027(calcium-independent cell-adhesion activity)\u5728\u7d30\u80de\u9593\u9699\u7684\u7dca\u5bc6\u9023\u63a5\u7279\u7570\u6027\u6d88\u9664\u4e2d\u8d77\u4e3b\u8981\u4f5c\u7528<\/p>\n

<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Cat. No.<\/td>\nHY500141<\/span><\/td>\n<\/tr>\n
Name<\/td>\nSensiStain\u2122 Anti-Claudin 18.2 Antibody<\/td>\n<\/tr>\n
Clone<\/td>\nIHC758<\/td>\n<\/tr>\n
Category<\/td>\nIHC Antibodies<\/td>\n<\/tr>\n
Gene Name<\/td>\nClaudin 18.2<\/td>\n<\/tr>\n
Application<\/td>\nELISA, IHC<\/td>\n<\/tr>\n
Raised In<\/td>\nRabbit<\/td>\n<\/tr>\n
Clonality<\/td>\nMonoclonal<\/td>\n<\/tr>\n
Reactivity<\/td>\nHuman<\/td>\n<\/tr>\n
Description<\/td>\nClaudin 18.2 is involved in tumor development and progression, has a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity, and is located in the outer cell membrane.<\/td>\n<\/tr>\n
Immunogen<\/td>\nRecombinant Protein<\/td>\n<\/tr>\n
Isotype<\/td>\nIgG<\/td>\n<\/tr>\n
Recommended Dilutions<\/td>\n1:50-1:200<\/td>\n<\/tr>\n
Storage Buffer<\/td>\nTris Buffer, pH 7.3 – 7.7, with 1% BSA and <0.1% Sodium Azide<\/td>\n<\/tr>\n
Storage Condition<\/td>\nThis product is stable for several weeks at 4\u00b0C as an undiluted liquid. Dilute only prior to immediate use. For extended storage aliquot contents and freeze at -20\u00b0C or below. Avoid cycles of freezing and thawing.<\/td>\n<\/tr>\n
Material Citation<\/td>\nIf use of this material results in a scientific publication, please cite the material in the following manner: Applied Biological Materials Inc, Cat. No. HY500141<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\u76f8\u95dc\u8a66\u5291\"\u00a0His Tag\u55ae\u682a\u6297\u9ad4\u00a0<\/a>\u00a0|\u00a0HA Tag\u00a0\u55ae\u682a\u6297\u9ad4<\/a>\u00a0| \u00a0GFP Tag \u00a0\u55ae\u682a\u6297\u9ad4<\/a>\u00a0|\u00a0D Tag \u00a0\u55ae\u682a\u6297\u9ad4\u00a0<\/a>\u00a0|GST Tag \u00a0\u55ae\u682a\u6297\u9ad4<\/a>\u00a0|\u00a0Myc\u00a0Tag \u00a0\u55ae\u682a\u6297\u9ad4<\/a>\u00a0|\u00a0\u00a0V5 Tag \u00a0\u55ae\u682a\u6297\u9ad4<\/a><\/strong><\/span><\/p>\n

\u7814\u7a76\u7d1a\u751f\u7269\u76f8\u4f3c\u85e5\u6297\u9ad4(research-grade biosimilar antibodies)<\/span>\u00a0<\/strong><\/span><\/p>\n

<\/p>\n

MedChemExpress (MCE) \u6291\u5236\u6027\u6297\u9ad4(Inhibitory Antibodies )\u662f\u7814\u7a76\u7d1a\u751f\u7269\u76f8\u4f3c\u85e5\u6297\u9ad4(research-grade biosimilar antibodies)\uff0c\u5177\u6709\u8207\u539f\u59cb\u6cbb\u7642\u6297\u9ad4\u76f8\u540c\u7684\u751f\u7269\u6d3b\u6027\u6210\u5206(bioactive component)\u3002\u751f\u7269\u76f8\u4f3c\u85e5( Biosimilar)\u4f7f\u5f97\u7814\u7a76\u85e5\u7269\u7684\u751f\u7269\u6548\u61c9\u6210\u70ba\u53ef\u80fd\u3002\u9019\u4e9b\u6297\u9ad4\u7279\u7570\u6027\u7d50\u5408\u6a19\u9776\u7d30\u80de\u6216\u86cb\u767d\u8cea\uff0c\u523a\u6fc0\u514d\u75ab\u7cfb\u7d71\u653b\u64ca\u60e1\u6027\u816b\u7624\u7d30\u80de\u6216\u963b\u65b7\u7279\u5b9a\u7d30\u80de\u53d7\u9ad4\u4f86\u963b\u6b62\u816b\u7624\u751f\u9577\u3002\u6a19\u9776\u86cb\u767d\u5305\u62ecCD20\u3001HER2\u3001EGFR\u3001VEGFR\u3001TNF-\u03b1\u7b49\u3002MCE\u6291\u5236\u6297\u9ad4\u5df2\u5ee3\u6cdb\u61c9\u7528\u65bc\u764c\u75c7(cancer)\u3001\u514d\u75ab\u5b78(immunology )\u548c\u611f\u67d3(infection)\u7b49\u6700\u71b1\u9580\u7684\u7814\u7a76\u9818\u57df\u3002<\/p>\n

MCE \u6291\u5236\u6297\u9ad4(MCE Inhibitory Antibodies)\u662f\u55ae\u682a\u6297\u9ad4 (mAb)\uff0c\u5df2\u5ee3\u6cdb\u61c9\u7528\u65bc\u764c\u75c7(cancer)\u3001\u514d\u75ab\u5b78( immunology )\u548c\u611f\u67d3(infection)\u7b49\u6700\u71b1\u9580\u7684\u7814\u7a76\u9818\u57df\u3002\u9019\u4e9b\u55ae\u682a\u6297\u9ad4\uff08mAb\uff09\u55ae\u4e00\u7279\u7570\u6027\u5730\u8207\u67d0\u4e9b\u7d30\u80de\u6216\u86cb\u767d\u8cea\u7d50\u5408\uff0c\u5f9e\u800c\u523a\u6fc0\u514d\u75ab\u7cfb\u7d71\u653b\u64ca\u60e1\u6027\u816b\u7624\u7d30\u80de\uff0c\u4e26\u900f\u904e\u963b\u65b7\u7279\u5b9a\u7684\u7d30\u80de\u53d7\u9ad4\u4f86\u9632\u6b62\u816b\u7624\u751f\u9577\u3002\u5b83\u5011\u53ef\u4ee5\u6291\u5236PD-1\u3001PD-L1\u3001EGFR\u3001VEGFR\u3001TNF-\u03b1 \u6216\u5176\u4ed6\u5728\u75be\u75c5\u4e2d\u7570\u5e38\u6d3b\u8e8d\u7684\u9776\u9ede\uff0c\u4f8b\u5982\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624(non-Hodgkin lymphom)\u3001A \u578b\u8840\u53cb\u75c5( Hemophilia A)\u3001\u814e\u7d30\u80de\u764c(renal cell carcinoma)\u3001\u5e15\u91d1\u68ee\u6c0f\u75c7(Parkinson’s disease)\u548c\u8f49\u79fb\u6027HER2 \u967d\u6027\u4e73\u764c\u764c\u75c7(metastatic HER2-positive breast cancer)\u3002\u4f8b\u5982\uff0c\u900f\u904e\u8207 VEGF \u7d50\u5408\uff0c\u8c9d\u4f10\u55ae\u6297(Bevacizumab )\u53ef\u9632\u6b62 VEGF \u8207\u5176\u53d7\u9ad4\u76f8\u4e92\u4f5c\u7528\uff0c\u5f9e\u800c\u6291\u5236\u65b0\u8840\u7ba1\u751f\u9577(inhibiting new vessel growth)\u3002\u862d\u535a\u5229\u73e0\u55ae\u6297(Lambrolizumab)\u9776\u5411\u6dcb\u5df4\u7d30\u80de\u7684\u7a0b\u5e8f\u6027\u7d30\u80de\u6b7b\u4ea1 1 (PD-1) \u53d7\u9ad4\u3002\u900f\u904e\u963b\u6b62\u5176\u914d\u9ad4\uff08PD-L1 \u548c PD-L2\uff09\u7684\u7d50\u5408\uff0cLambrolizumab \u8a98\u5c0e\u6297\u816b\u7624\u514d\u75ab\u53cd\u61c9\u3002<\/p>\n

<\/p>\n

Zolbetuximab (IMAB362)\u00a0 | CAS#1496553-00-4 MCE\u8ca8\u865fHY-P99058 \u00a096.98%<\/a><\/span><\/strong><\/span><\/p>\n

(Synonyms: IMAB362)<\/p>\n

\n
\n

Zolbetuximab (IMAB362) \u662f\u4e00\u7a2e\u91dd\u5c0d Claudin-18.2 \u7684\u55ae\u682a\u6297\u9ad4\u3002 Zolbetuximab \u900f\u904e\u514d\u75ab\u6548\u61c9\u6a5f\u5236\u4ecb\u5c0e Claudin-18.2 \u967d\u6027\u7d30\u80de\u7684\u7279\u7570\u6027\u6bba\u50b7\u3002 Zolbetuximab \u53ef\u7528\u65bc\u80c3\u8178\u9053\u817a\u764c(gastrointestinal adenocarcinomas )\u548c\u80f0\u817a\u816b\u7624( pancreatic tumors)\u7684\u7814\u7a76\u3002Zolbetuximab (0-100 \u03bcg\/mL) \u8207 CLDN18.2+ PC \u7d30\u80de\u7d50\u5408\uff0c\u8a98\u5c0e\u6297\u9ad4\u4f9d\u8cf4\u6027\u7d30\u80de\u6bd2\u6027 (antibody-dependent cellular cytotoxicity, ADCC) \u548c\u88dc\u9ad4\u4f9d\u8cf4\u6027\u7d30\u80de\u6bd2\u6027 (complement-dependent cytotoxicity, CDC)[1]\u3002<\/p>\n

\n

Zolbetuximab Related Antibodies<\/span><\/strong><\/span><\/h3>\n<\/div>\n
\n